Anavex Life Sciences Corp (AVXL)

[XenaLives]

Stat sig topline results are not necessary for approval.

Substantial relief where there is none for all patients will be adequate.

We are not dealing with typical symptomatic treatment here, the MOA addresses the root cause of the dysfunction, cellular homeostasis, so I expect benefit to be wide spread.

The scenario I have in mind is that about 25% of patients across treatment arms may respond well, which is unlikely to yield stat sig topline results.